Rochester Medical announced it has entered into M&A deals with C. R. Bard at a price of $20 per share, or approximately $262 million in the aggregate.
The Rochester Medical Board of Directors unanimously approved the M&A deals and will recommend that the Company's shareholders approve the transaction.
Under the terms of the merger agreement, Rochester Medical shareholders will receive $20 in cash for each share that they hold at the closing of the merger, representing a 37 percent premium over the Company's average closing price during the 90 trading days ended September 3, 2013, as part of the M&A deals.
The M&A deals are subject to certain closing conditions specified in the definitive agreement, including regulatory approvals and the approval of Rochester Medical's shareholders.
The M&A deals transaction is expected to close in the fourth calendar quarter of 2013.
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity